 A large number of molecular alterations are under study for their prognostic impact in AML . However , only FLT3 @-@ <unk> , <unk> , <unk> and c @-@ KIT are currently included in <unk> international risk <unk> <unk> . These are expected to increase rapidly in the near future . FLT3 internal tandem <unk> ( <unk> ) have been shown to confer a poorer prognosis in AML with normal cytogenetics . Several FLT3 inhibitors have undergone clinical trials , with mixed results . Two other mutations - <unk> and <unk> <unk> are associated with improved outcomes , especially in people with normal cytogenetics and are used in current risk <unk> algorithms . 
